The CONSORT Patient-Reported Outcome (PRO) extension: Implications for clinical trials and practice

Health and Quality of Life Outcomes

Volumn 11, Issue 1, 2013, Pages

  Calvert, Melanie ^a   Brundage, Michael ^b   Jacobsen, Paul B ^c   Schünemann, Holger J ^d   Efficace, Fabio ^e  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN S UNIVERSITY   (Canada)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e GIMEMA Data Center   (Italy)

Author keywords

Clinical trials; CONSORT PRO; Quality of life; Reporting

Indexed keywords

CLINICAL PRACTICE; HEALTH CARE POLICY; HEALTH STATUS; HUMAN; INFORMATION PROCESSING; MEDICAL LITERATURE; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT REPORTED OUTCOME; PRACTICE GUIDELINE; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; REVIEW; STUDY DESIGN; VALIDITY;

CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; ITALY; PATIENT OUTCOME ASSESSMENT; PATIENT SATISFACTION; POLICY MAKING; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84886416556     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-11-184     Document Type: Review

References (27)

1. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998, 317:1191-1194. 10.1136/bmj.317.7167.1191, 28701, 9794853.
2. US Food and Drug Administration: Guidance for Industry Patient-reported outcome measures: use in medical product development to support labeling claims. U.S. Department of health and human services food and drug administration. 2009, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf, US Food and Drug Administration: Guidance for Industry.
3. Till JE, Osoba D, Pater JL, Young JR. Research on health-related quality of life: dissemination into practical applications. Qual Life Res 1994, 3:279-283. 10.1007/BF00434902, 7812281.
4. Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: the example of health related quality of life-a European guidance document for the improved integration of health related quality of life assessment in the drug regulatory process. Drug Inf J 2002, 36:209-238.
5. Brundage M, Bass B, Jolie R, Foley K. A knowledge translation challenge: clinical use of quality of life data from cancer clinical trials. Qual Life Res 2011, 20:979-985. 10.1007/s11136-011-9848-0, 21279446.
6. Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol 2007, 18:775-781.
7. Brundage M, Bass B, Davidson J, Queenan J, Bezjak A, Ringash J, Wilkinson A, Feldman-Stewart D. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res 2011, 20:653-664. 10.1007/s11136-010-9793-3, 21110123.
8. Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'Haese S, Zurlo A. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision making?. J Clin Oncol 2003, 21:3502-3511. 10.1200/JCO.2003.12.121, 12972527.
9. Bottomley A, Therasse P. Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol 2002, 3:620-628. 10.1016/S1470-2045(02)00876-8, 12372724.
10. Efficace F, Bottomley A, van Andel G. Health related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. Cancer 2003, 97:377-388. 10.1002/cncr.11065, 12518362.
11. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013, 309:814-822. 10.1001/jama.2013.879, 23443445.
12. Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, Dias S, Schulz KF, Plint AC, Moher D. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev 2012, 11. MR000030.
13. The CONSORT statement 2010. http://www.consort-statement.org/consort-statement/overview0/.
14. EQUATOR network. http://www.equator-network.org/.
15. Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, Efficace F, King M, Lam CL, Moher D, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res 2013, 22:1161-1175. 10.1007/s11136-012-0252-1, 3731511, 22987144.
16. Hopewell S, Altman DG, Moher D, Schulz KF. Endorsement of the CONSORT statement by high impact factor medical journals: a survey of journal editors and journal 'Instructions to Authors'. Trials 2008, 9:20. 10.1186/1745-6215-9-20, 2359733, 18423021.
17. Hopewell S, Ravaud P, Baron G, Boutron I. Effect of editors' implementation of CONSORT guidelines on the reporting of abstracts in high impact medical journals: interrupted time series analysis. BMJ 2012, 344:e4178. 10.1136/bmj.e4178, 3382226, 22730543.
18. Kerner JF, Guirguis-Blake J, Hennessy KD, Brounstein PJ, Vinson C, Schwartz RH, Myers BA, Briss P. Translating research into improved outcomes in comprehensive cancer control. Cancer Causes Control 2005, 16(Suppl 1):27-40.
19. Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the Use of existing instruments and their modification PRO task force report. Value Health 2009, 12:1075-1083. 10.1111/j.1524-4733.2009.00603.x, 19804437.
20. Efficace F, Feuerstein M, Fayers P, Cafaro V, Eastham J, Pusic A, Blazeby J, EORTC Quality of Life Group (Patient Reported Outcome Measurements Over Time In ONcology-PROMOTION Project) Patient-reported outcomes in randomized controlled trials of prostate cancer: methodological quality and impact on clinical-decision-making. Eur Urol 2013, in press, EORTC Quality of Life Group (Patient Reported Outcome Measurements Over Time In ONcology-PROMOTION Project).
21. Fayers P, Hays R. Assessing quality of life in clinical trials 2005, New York: Oxford University Press.
22. Al-Marzouki S, Roberts I, Evans S, Marshall T. Selective reporting in clinical trials: analysis of trial protocols accepted by the lancet. Lancet 2008, 372:201.
23. World health organization. Guidelines for development of WHO guidelines. 2003, http://whqlibdoc.who.int/hq/2003/EIP_GPE_EQC_2003_1.pdf.
24. Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, Liberati A, O'Connell D, Oxman AD, Phillips B, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches the GRADE working group. BMC Health Serv Res 2004, 4:38. 10.1186/1472-6963-4-38, 545647, 15615589.
25. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schünemann HJ, GRADE Working Group Rating quality of evidence and strength of recommendations: going from evidence to recommendations. BMJ 2008, 336:1049-1051. 10.1136/bmj.39493.646875.AE, 2376019, 18467413, GRADE Working Group.
26. Qaseem A, Forland F, Macbeth F, Ollenschlager G, Phillips S, van der Wees P. Guidelines international network: toward international standards for clinical practice guidelines. Ann Intern Med 2012, 156:525-531. 10.7326/0003-4819-156-7-201204030-00009, 22473437.
27. IOM (Institute-of-Medicine) Clinical Practice Guidelines We Can Trust 2011, Washington, DC: The National Academies Press, IOM (Institute-of-Medicine).